Background: Hypertensive with impaired fasting glucose is the basic expression of metabolic syndrome. Objectives: To study the IR and the correlation between Fasting Plasma Insulin (FPI) and Fasting Plasma Glucose (FPG) concentration in hypertensive patients with Impaired Fasting Glucose (IFG). Subjects and method: The descriptive, cross-sectional study was carried out on 38 hypertensive patients with IFG (IFG group) and 30 hypertensive patients without IFG (control group). The data were collected and analyzed by SPSS 11.5 software. Results:The FPI and IR index in the IFG group were 14.6+/-5.2 micro mol/ml and 3. 94+/- l.40, respectively, higher than in the control group (9.6+/-4.2 micro mol/ml and 2.17+/-0.99/ respectively) with p<0.00l. There was a positive correlation between FPI and FPG systolic blood and diastolic blood pressure/ with correlation coefficients were 0.4/ 0.48 and 0.46/ respectively (p<0.00l). Conclusion: There was an increase of FPI and IR index in the hypertensive patients with IFG compared to those without IFG. \r\n', u'\r\n', u'
Insulin resistance ; hypertensive patients ; impaired fasting glucose.

BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is related to the pathogenesis and poor outcome of numerous types of carcinomas, including gastric carcinoma. Gastric cancer patients with HER2 positivity have become potential candidates for targeted therapy with trastuzumab. METHODS: We investigated 208 gastric cancer specimens using immunohistochemistry (IHC), fluorescence in situ hybridization and dual in situ hybridization (ISH). We also investigated the concordance between IHC and ISH. The correlation between HER2 status and various clinicopathological findings was also investigated. RESULTS: In total, 15.9% (33/208) and 24.5% (51/208) of gastric cancers showed HER2 gene amplification and protein overexpression, respectively. A high level of concordance between ISH and IHC analyses (91.3%, κ = 0.76) was found. A significant correlation between HER2 status and intestinal-type (p < .05) and differentiated carcinomas (p < .05) was also noted. The HER2 heterogeneity was high in gastric cancers; we found 68.8% phenotypic heterogeneity and 57.6% genotypic heterogeneity. Heterogeneity in HER2 protein expression and gene amplification showed a close association with diffuse histologic type and IHC 2+. CONCLUSIONS: HER2 protein overexpression and gene amplification were detected in 24.5% and 15.9% of gastric cancer specimens, respectively. Intestinal-type showed a higher level of HER2 protein overexpression and gene amplification than diffuse type. HER2 status also showed a significant relationship with well- and moderately-differentiated carcinomas. The ratio of phenotypic and genotypic heterogeneity of HER2 was high in gastric carcinomas and was associated with HER2 IHC 2+ and diffuse histologic type.
Asian Continental Ancestry Group* ; Fluorescence ; Gene Amplification ; Genes, erbB-2 ; Humans ; Immunohistochemistry ; In Situ Hybridization ; Population Characteristics* ; Receptor, Epidermal Growth Factor ; Stomach Neoplasms ; Trastuzumab